SCHEMBL2329610

SCHEMBL2329610

Clc1cc(-c2ccccc2)ccn1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 2/20 0.56
ADORA1 P30542 1/20 0.56
TRPA1 O75762 1/20 0.52
NOTUM Q6P988 1/20 0.48
IDO1 P14902 2/20 0.47
PLAU P00749 1/20 0.47
TDP1 Q9NUW8 1/20 0.46
CYP19A1 P11511 1/20 0.45
CCNC P24863 1/20 0.45
CDK8 P49336 1/20 0.45
CNR1 P21554 1/20 0.44
PIK3CA P42336 1/20 0.43
CYP1A2 P05177 1/20 0.42
RECQL P46063 1/20 0.42
ESR2 Q92731 1/20 0.42
LOX P28300 1/20 0.42
LOXL3 P58215 1/20 0.42
LOXL2 Q9Y4K0 1/20 0.42
FDPS P14324 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29461217 1.00 ADORA2A (0.56) ADORA2AADORA1TRPA1NOTUMIDO1
SCHEMBL25070215 0.98 ADORA2A (0.54) ADORA2AADORA1TRPA1NOTUMIDO1
SCHEMBL4027001 0.88 IDO1 (0.55) ADORA2AADORA1TRPA1IDO1TDP1
SCHEMBL18770607 0.85 ADORA2A (0.51) ADORA2AADORA1TRPA1IDO1CYP19A1
SCHEMBL29701969 0.85 ADORA2A (0.51) ADORA2AADORA1TRPA1IDO1CYP19A1
SCHEMBL4672168 0.84 LMNA (0.52) ADORA2AADORA1NOTUMIDO1CYP19A1
SCHEMBL18253554 0.84 ADORA2A (0.54) ADORA2AADORA1TRPA1IDO1CYP19A1
SCHEMBL28796964 0.83 LTA4H (0.50) ADORA2AADORA1TRPA1CYP1A2
SCHEMBL3500189 0.82 MAP4K4 (0.49) ADORA2AADORA1IDO1CCNCCDK8
SCHEMBL12337654 0.81 KDM4E (0.49) ADORA2AADORA1TRPA1IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 280 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122071492-A Organic electroluminescent material and device 环球展览公司 2026-05-22 CN disclosed
US-20260143904-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2026-05-21 US disclosed
US-20260116906-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2026-04-30 US disclosed
US-20260035398-A1 TETRADENTATE AND OCTAHEDRAL METAL COMPLEXES CONTAINING NAPHTHYRIDINOCARBAZOLE AND ITS ANALOGUES UNIV ARIZONA STATE (US) 2026-02-05 US disclosed
US-12390463-B2 Dosage forms and regimens for amino acid compounds PLIANT THERAPEUTICS, INC. (US) 2025-08-19 US disclosed
US-20250223288-A1 AMINO ACID COMPOUNDS AND METHODS OF USE PLIANT THERAPEUTICS, INC. 2025-07-10 US disclosed
US-12312366-B2 Tetradentate and octahedral metal complexes containing naphthyridinocarbazole and its analogues ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2025-05-27 US disclosed
EP-4520329-A2 TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS Pliant Therapeutics, Inc. (US) 2025-03-12 EP disclosed
US-12247042-B2 Organic electroluminescent materials and devices UNIVERSAL DISPLAY CORPORATION (US) 2025-03-11 US disclosed
EP-4509512-A2 AMINO ACID COMPOUNDS AND METHODS OF USE Pliant Therapeutics, Inc. (US) 2025-02-19 EP disclosed
US-20060009455-A1 especially blood coagulation factor XIa and plasma kallikrein; e.g. 4-aminomethyl-[2-phenyl-1-(4-phenyl-pyridin-2-yl)-ethyl]-trans cyclohexanecarboxamide; anticoagulant, antiinflammatory agent; BRISTOL-MYERS SQUIBB COMPANY 2006-01-12 US disclosed
WO-2005123680-A1 SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2005-12-29 WO disclosed
CN-1659172-A Cross-metathesis of olefins directly substituted with an electron-withdrawing group using transition metal carbene catalysts CALIFORNIA INST OF TECHN (US) 2005-08-24 CN disclosed
EP-1562934-A1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LTD. (GB) 2005-08-17 EP disclosed
WO-2004046133-A1 AMINO-HETEROCYCLES AS VR-1 ANTAGONISTS FOR TREATING PAIN MERCK SHARP & DOHME LIMITED (GB) 2004-06-03 WO disclosed
US-6693210-B2 USING PALLADIUM, NICKEL PHOSPHINE COMPLEX AS CATALYSTS MITSUBISHI RAYON CO., LTD. (JP) 2004-02-17 US disclosed
US-20030065208-A1 Using palladium, nickel phosphine complex as catalysts MITSUBISHI RAYON CO., LTD. (JP) 2003-04-03 US disclosed
EP-1270582-A1 TRIPHENYLPHOSPHINE DERIVATIVE, PRODUCTION PROCESS THEREFOR, PALLADIUM COMPLEX THEREOF, AND PROCESS FOR PRODUCING BIARYL DERIVATIVE Mitsubishi Rayon Co., Ltd. (JP) 2003-01-02 EP disclosed
US-4831034-A 4-benzylpiperazines useful as neuroleptics RHONE-POULENC SANTE (FR) 1989-05-16 US disclosed
EP-0036638-A2 Herbicidal and plant growth regulant 2-sulfinyl and 2-sulfonyl pyridine N-oxides DIAMOND SHAMROCK CORPORATION (US) 1981-09-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009455-A1 especially blood coagulation factor XIa and plasma kallikrein; e.g. 4-aminomethyl-[2-phenyl-1-(4-phenyl-pyridin-2-yl)-ethyl]-trans cyclohexanecarboxamide; anticoagulant, antiinflammatory agent; F12, F11, F2 ADORA2A 3094/4885ADORA1 2458/4885TRPA1 2572/4885
US-20260035398-A1 TETRADENTATE AND OCTAHEDRAL METAL COMPLEXES CONTAINING NAPHTHYRIDINOCARBAZOLE AND ITS ANALOGUES LBR, SCO2, RAD54L ADORA2A 2579/4885ADORA1 1432/4885TRPA1 2824/4885
US-12390463-B2 Dosage forms and regimens for amino acid compounds ITGB6, ITGA6, ITGAV ADORA2A 2441/4885ADORA1 666/4885TRPA1 3944/4885
US-20030065208-A1 Using palladium, nickel phosphine complex as catalysts PDCD1LG2, PIK3CA, PDCD1 ADORA2A 4248/4885ADORA1 4734/4885TRPA1 3968/4885
US-20250223288-A1 AMINO ACID COMPOUNDS AND METHODS OF USE ITGB6, ITGA6, ITGA5 ADORA2A 2762/4885ADORA1 930/4885TRPA1 3323/4885
US-12247042-B2 Organic electroluminescent materials and devices OCIAD2, OCIAD1, RER1 ADORA2A 1891/4885ADORA1 1836/4885TRPA1 1056/4885
US-20260116906-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES LBR, OXSR1, RER1 ADORA2A 2411/4885ADORA1 1420/4885TRPA1 2019/4885
US-12312366-B2 Tetradentate and octahedral metal complexes containing naphthyridinocarbazole and its analogues PAICS, DNTT, PNPO ADORA2A 3140/4885ADORA1 3368/4885TRPA1 582/4885
US-20260143904-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES LBR, OPRD1, OXSR1 ADORA2A 3098/4885ADORA1 1781/4885TRPA1 909/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.